InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective on the stock.

InspireMD Stock Performance

NYSE:NSPR opened at $2.70 on Wednesday. The stock has a 50-day simple moving average of $2.86 and a 200 day simple moving average of $2.75. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.80. The company has a market cap of $80.16 million, a PE ratio of -3.60 and a beta of 0.88.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in shares of InspireMD during the 4th quarter worth approximately $27,000. Legato Capital Management LLC acquired a new position in InspireMD during the fourth quarter worth $47,000. Schonfeld Strategic Advisors LLC raised its position in InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after acquiring an additional 18,233 shares in the last quarter. Northern Trust Corp lifted its stake in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after acquiring an additional 24,452 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in shares of InspireMD in the 4th quarter valued at about $191,000. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.